Lassen Therapeutics: Funding, Investors & Team (Sep 2026)
Lassen Therapeutics specializes in developing antibodies for potential treatments in fibrosis, rare diseases, and oncology. Their leading candidate, LASN01, is a monoclonal antibody designed to target IL-11 receptor alpha (IL-11R). IL-11, a cytokine belonging to the IL-6 family, plays a crucial role in fibrosis and is a significant factor in tumor microenvironment organization and tumor growth. In comparison to targeting other factors such as TGF-β and CTGF, blocking the activity of IL-11 shows promising potential for enhanced effectiveness. The IL-11 protein acts as a mediator between cancer cells and stromal cells, making it a pivotal component in the interaction between the two.
Lassen Therapeutics has raised $85.0M across 1 funding round on record, the most recent a Series B of $85.0M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lassen Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Lassen Therapeutics Funding Rounds
Lassen Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Lassen Therapeutics Funding Compared to Other Biotechnology Startups
Lassen Therapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lassen Therapeutics in Biotechnology and San Diego
Companies Similar to Lassen Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Lassen Therapeutics Funding FAQs
What does Lassen Therapeutics do?
Lassen Therapeutics specializes in developing antibodies for potential treatments in fibrosis, rare diseases, and oncology. Their leading candidate, LASN01, is a monoclonal antibody designed to target IL-11 receptor alpha (IL-11R). IL-11, a cytokine belonging to the IL-6 family, plays a crucial role in fibrosis and is a significant factor in tumor microenvironment organization and tumor growth. In comparison to targeting other factors such as TGF-β and CTGF, blocking the activity of IL-11 shows promising potential for enhanced effectiveness. The IL-11 protein acts as a mediator between cancer cells and stromal cells, making it a pivotal component in the interaction between the two.
How much funding has Lassen Therapeutics raised?
Lassen Therapeutics has raised $85.0M across 1 round on record. The most recent is a Series B of $85.0M announced in Dec 2023.
When did Lassen Therapeutics last raise funding?
Lassen Therapeutics' most recent funding round on record is a Series B of $85.0M, announced in Dec 2023.
Who founded Lassen Therapeutics?
FundedIQ lists David King (Founder) at Lassen Therapeutics.
Where is Lassen Therapeutics headquartered?
Lassen Therapeutics is based in San Diego, California, United States.
How many employees does Lassen Therapeutics have?
Lassen Therapeutics is in the 11-50 employee band.
How does Lassen Therapeutics' funding compare to other Biotechnology startups?
Lassen Therapeutics' latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Lassen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lassen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.